The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update. [PDF]
Jakubowska A, Roux CWL, Viljoen A.
europepmc +1 more source
The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis. [PDF]
Qeadan F, McCunn A, Tingey B.
europepmc +1 more source
A Case Report of Systemic Allergic Reaction to the Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonist Tirzepatide. [PDF]
Le TTB +4 more
europepmc +1 more source
Effect of Dual Glucagon-Like Peptide 1/Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist (Tirzepatide) versus Bariatric Surgery on Weight Loss and Nonalcoholic Fatty Liver Disease. [PDF]
Al-Sabah S +18 more
europepmc +1 more source
Expression of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in the rat submandibular gland is influenced by pre- and post-natal high-fat diet exposure. [PDF]
Sangsuriyothai P +5 more
europepmc +1 more source
The impact of cinnamon on glucose levels and alcohol cravings in early recovery
Morshead-Metelica, Jeanna
core +1 more source
Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease
Accumulating evidence suggests that glucose-dependent insulinotropic polypeptide (GIP) in addition to its involvement in type 2 diabetic pathophysiology may be involved in the development of obesity and the pathogenesis of cardiovascular disease. In this
Sebastian M Heimburger +2 more
exaly +2 more sources

